Kintara Pharma (KTRA) - שולי הרווח הגולמי

The gross margin chart demonstrates the results of outsourcing final molecule testing to external CRO centers, with the current value recorded at 0.00. Kintara Therapeutics (KTRA) focuses on therapies for severe brain tumors, which guarantees demand upon drug release. The new structure following the merger with TuHura possesses clinical expertise, yet maintains high financial risks until the first revenue is generated.
פילוחי מדדים פיננסיים ומדדי שוק עבור Kintara Therapeutics Inc (KTRA)

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product creation costs. By analyzing the gross margin percentage, an investor can filter out random expense fluctuations and assess the fundamental profitability of assets. For Kintara Therapeutics (KTRA), this metric is secondary, as the success of a biotech firm depends on FDA approval rather than macroeconomic cycles.